Table S1. The list of all plasmids constructed or used in this study

Plasmid	Characteristics	Oligos used to amplify the insert	
For PAN expression		0 - g oo om on to marp	
pJM1	Ap ^r ; pcDNA 3 (Invitrogen) with a KpnI- XhoI insert of 1076 bp, corresponding to PAN wt	oJM1 and oJM2	
pJM2	Ap ^r ; pcDNA 3 with a KpnI-XhoI insert of 998 bp, corresponding to PAN carrying the mutation A1 (deletion of 28667 to 28745)	oJM5 and oJM2	
pJM3	Ap ^r ; pcDNA 3 with a KpnI-XhoI insert of 998 bp, corresponding to PAN carrying the mutation $A3h$ (delation of 20634 to 20742)	oJM1 and oJM3	
pJM4	Ap ^r ; pcDNA 3 with a KpnI-XhoI insert of 866 bp, corresponding to PAN carrying mutation the $\Delta 3$ (deletion of 29553 to 29742)	oJM1 and oJM4	
pJM7	Ap ^r ; pcDNA 3 with a KpnI-XhoI insert of 889 bp, corresponding to PAN carrying the mutation $\Delta 1$ and 3b	oJM5 and oJM3	
pJM8	Ap ^r ; pcDNA 3 with a KpnI-XhoI insert of 973 bp, corresponding to PAN carrying the mutation Δ MREa (28667 to 28692)	oJM16 and oJM2	
рЈМ10	Ap ^r ; pcDNA 3 with a KpnI-XhoI insert of 938 bp, corresponding to PAN carrying the mutation Δ MREc (deletion of 28667 to 28727)	oJM18 and oJM2	
pJM11	Ap ^r ; pcDNA 3 with a KpnI-XhoI insert of 1013 bp, corresponding to PAN carrying the point mutations (KSHV 28704-28712 TATGGATTT to CTGCACGTC)	oJM19 and pJM2	
pJM17	Ap ^r ; pcDNA 3 with a KpnI-XhoI insert of 1025 bp, corresponding to PAN carrying the mutation Δ MRE-d (internal deletion of the MRE-II)	oJM25 and oJM2	
pJM53	Ap ^r ; CMV promoter was excised from pcDNA 3 by PAN Promoter + PAN (2092 bp) at MluI-XhoI site	PAN promoter + PAN insert was amplified using oJM79 and oJM2 as primers	
pJM54	Ap ^r ; pJM53 with PAN carrying the point mutations (KSHV 28704-28712 TATGGATTT to CTGCACGTC)	Mutation created by amplifying two fragments using two oligo pairs: oJM83/oJM2 and oJM84/oJM79. Fragment overlapped using oJM2/oJM79	
pJM55	Ap ^r ; pcDNA 3 with a KpnI-XhoI insert of 950 bp, corresponding to PAN∆2 carrying an internal deletion from 29019-29068	Mutation created by amplifying two fragments using two oligo pairs: oJM82/oJM1 and oJM81/oJM2. Fragment overlapped using oJM1/oJM2	
For K5 expression			
pJM5	Ap ^r ; pcDNA 3 with a HindIII-XhoI insert of 803 bp, corresponding to wt K5	oJM9 and oJM10	
FOR VGPUK expression		B(10 1 B(12	
pJM6	Ap; pcDNA 3 with a HindIII-Xhol insert of 1061 bp, corresponding to wt vGPCR	OJM12 and OJM13	
pJW112	Ap ; pJMo plus an insert in the 5' Hindlil site corresponding to PAN MRE-II, in antisense orientation upstream	oJM20/oJM21	
pJM13	Ap ^r ; pJM6 plus an insert in the 5' HindIII site corresponding to PAN MRE-II, sense	MRE-II insert was generated by annealing oligos oJM20/oJM21	
pJM18	Ap ^r ; pJM6 plus an insert in the 5' HindIII site corresponding to PAN-MRE, sense	PAN MRE element was amplified using oligo pair oJM23/oJM24	

For Luciferase and Renilla			
expression			
pMIR-REPORT-Luciferase	Ap ^r for luciferase expression purchased		
piville reli orer Eucliciuse	from Applied Biosystems		
pRL-TS	For Renilla expression, original from		
pitte 15	reference 40		
pIM19	Ap ^r : pMIR-REPORT-Luciferase plus an	PAN MRE element was amplified using oligo pair	
Points	insert corresponding to the entire PAN	oJM28/oJM29	
	MRE element, cloned upstream of		
	Luciferase using the plasmid's BamHI site		
pJM43	Ap ^r ; pMIR-REPORT-Luciferase plus an	PAN ENE element was amplified using oligo pair	
Ł	insert corresponding to ENE element cloned	oJM66/oJM67	
	in the HindIII site at the 3' of Luciferase		
	ORF		
pJM44	Ap ^r ; pJM19 with an ENE element in the	The same oligo sets for pJM19 and pJM 43 were	
-	HindIII site at the 3' if Luciferase ORF	used for the insertions	
psiCHECK2,	Apr; for dual Renilla and Luciferase		
	expression, purchased from Promega		
pJM47	Ap ^r ; psiCHECK2 plus an insert	PAN MRE element was amplified using oligo pair	
	corresponding to the entire PAN MRE	oJM69/oJM70	
	element, cloned upstream of Renilla using		
	plasmid's XbaI site.		
pJM48	Ap'; psiCHECK2 plus PAN MRE element,	PAN MRE element was amplified using oligo pair	
	cloned in Xbal site upstream of <i>Renilla</i> in	oJM69/oJM70	
	reverse or antisense orientation		
pJM49	Ap'; psiCHECK2 plus an insert	PAN ENE element was amplified using oligo pair	
	corresponding to ENE element cloned in the	oJM/1 and oJM/2	
B (50	A DESCRIPTION AND AND AND AND AND AND AND AND AND AN		
рлизо	Ap'; psiCHECK2 plus PAN ENE element,	PAN ENE element was amplified using oligo pair	
	in reverse or antisense orientation	0J1VI / 1/0J1VI / Z	
	in reverse of antisense orientation		

Characteristics include antibiotics resistance (Apr, ampicillin resistant), parent vectors, cloned inserts and brief cloning strategies. DNA oligo names and nt positions in the KSHV genome are provided for the construction of the specified plasmid.

Table S2. The list of oligos used in this study

Oligo name	Position	Features*	Sequence (5' to 3')
oJM1	KSHV PAN nt 28667-28683	F with Asp718	AGTCGGGTACC/ACTGGGACTGCCCAGTC
oJM2	KSHV PAN nt 29742-29720	B with XhoI	AGTCCGCTCGAG/ATGGATTAAACATTGACCTTTAT
oJM3	KSHV PAN nt 29634-29612	B with XhoI	AGTCCGCTCGAG/CCAATATACACTGGGATAAAAAC
oJM4	KSHV PAN nt 29553-29531	B with XhoI	AGTCCGCTCGAG/CCGTTATCATTGTTACACAACGC
oJM5	KSHV PAN nt 28745-28762	F with Asp718	AGTCGGGTACC/GTTTTCATTGGTGCCGCC
oJM7	KSHV PAN nt 29542-29520	в	GTTACACAACGCTTTCACCTACA
oJM9	KSHV K5 nt 25701-25720	B with XhoI	AGTCCGCTCGAG/CCAAGTGGTTGTTCAACCGT
oJM10	KSHV K5 nt 26489-26472	F with HindIII	ATCGTAAGCTT/GCAGAGATGGCGTCTAAG
oJM12	KSHV vGPCR nt 129345- 129369	F with HindIII	ATCGTAAGCTT/CACCTATACTACTTGTTATTGTAGG
oJM13	KSHV vGPCR nt 130405- 130389	B with XhoI	AGTCCGCTCGA/GCGGGCTACGTGGTGGC
oJM16	KSHV PAN nt 28692-28714	F with Asp718	AGTCGGGTACC/TGCCGCTTCACCTATGGATTTTG
oJM18	KSHV PAN nt 28727-28746	F with Asp718	AGTCGGGTACC/GCCTTCTTGCCGCTTCTGGT
oJM19	KSHV PAN nt 28692-28729	F with Asp718	AGTCGGGTACC/TGCCGCTTCACCCTGCACGTCTGTGCTCGCTGCTTGCC
oJM20	KSHV PAN nt 28689-28729	F with HindIII	AGCTT/GGCTGCCGCTTCACCTATGGATTTTGTGCTCGCTGCTTGCC/A
oJM21	KSHV PAN nt 28729-28689	B with HindIII	AGCTT/GGCAAGCAGCGAGCACAAAATCCATAGGTGAAGCGGCAGCC/A
oJM23	KSHV PAN nt 28667-28684	F with HindIII	ATACCCAAGCTT/ACTGGGACTGCCCAGTCA
oJM24	KSHV PAN nt 28750-28732	B with HindIII	ATACCCAAGCTT/GAAAACCAGAAGCGGCAAG
oJM25	KSHV PAN nt 28667- 28691/nt 28272-28744	F with Asp718	AGTCGGGTACC/ACTGGGACTGCCCAGTCACCTTGGC/GCCTTCTTGCC GCTTCTG
oJM28	KSHV PAN nt 28667-28683	F with BamHI	TACTCAGGATCC/ACTGGGACTGCCCAGTC
oJM29	KSHV PAN nt 28750-28732	B with BamHI	TACTCAGGATCC/GAAAACCAGAAGCGGCAAG
oJM32	KSHV PAN nt 28698-28709	RNA oligomer	Biotin-GGCUGCCGCUUCACCUAUGGA
oJM33	KSHV PAN nt 28709-28729	RNA oligomer	Biotin-AUUUUGUGCUCGCUGCUUGCC
oJM34	KSHV PAN nt 28729-28750	RNA oligomer	Biotin-CUUCUUGCCGCUUCUGGUUUUC
oJM35	KSHV PAN nt 28697-28720	RNA oligomer	Biotin-CUUCACCUAUGGAUUUUGUGCUCG
oJM66	KSHV PAN nt 29530-29554	F with HindIII	ATACCCAAGCTT/AGCGTTGTGTAACAATGATAACGGT
oJM67	KSHV PAN nt 29666-29641	B with HindIII	TGCATGAAGCTT/ACGTTAAATTGTCAAAAGTATAACAT
oJM68	KSHV PAN nt 28697-28720	RNA oligomer	Biotin-CUUCACCCUGCACGUCUGUGCUCG
oJM69	KSHV PAN nt 28667-28685	F with XbaI	ATGCTCTAGA/ACTGGGACTGCCCAGTCAC
oJM70	KSHV PAN nt 28750-28732	B with XbaI	ATGATCTAGA/GAAAACCAGAAGCGGCAAG
oJM71	KSHV PAN nt 29530-29554	F with XhoI	TCAATACTCGAG/AGCGTTGTGTAACAATGATAACGGT
oJM72	KSHV PAN nt 29666-29641	B with XhoI	TACATGCTCGAG/ACGTTAAATTGTCAAAAGTATAACAT
oJM79	KSHV PAN nt 27650-27673	F with MluI	GCAGCACGCGT/AAGGTGTGAGGGTTTCTAAGAAAC
oJM81	KSHV PAN nt 29006- 29018/29069-29089	F	CCTTTTATGATAT/AGCGCCCACTGGTGTATCAGA
oJM82	KSHV PAN nt 29083- 29069/29018-28996	В	ACACCAGTGGGCGCT/ATATCATAAAAGGGGGGCTACAAC
oJM83	KSHV PAN nt 28692-28729	F	TGCCGCTTCACC <u>CTGCACGTC</u> TGTGCTCGCTGCTTGCC
oJM84	KSHV PAN nt 28722-28684	В	AGCGAGCACA <u>GACGTGCAG</u> GGTGAAGCGGCAGCCAAGGT
oST197	Human U6	В	AAAATATGGAACGCTTCACGA
oVM11	KSHV ORF57 nt 82296-82277	В	CTCGTCTTCCAGTGTCGGTG
oVM52	KSHV PAN nt 29400-29419	F	CTAAAGTGGTGTGCGGCAGC
oZMZ243	T7 Promoter	В	CTATAGTGAGTCGTATTAAT
oZMZ270	Human GAPDH, NM_002046	В	TGAGTCCTTCCACGATACCAAA
PAN P	KSHV PAN nt 29181-29205	F, TaqMan	56-FAM/TTGAGTGTAAATCGGGCCACTTTGC/3IABkFG
PAN 1	KSHV PAN nt 29122-29143	F, TaqMan	GTTTCGGTTCTGTGTTTGTCTG
PAN 2	KSHV PAN nt 29249-29227	B, TaqMan	CACAACGCACCAATAAGATACAC

* F, forward; B, backward



С		29632	29658
•			
1	29544 29554 CGGCAAGGUUUUUAUCCCAG	UGUAUAUUGGAAAAACAUGUUAUA	
1	C CAGACGGCAAGGUUUUUAUCCCAG	UGU	
2	GUUUUGGCUGGGUUUUUCCUUGUUCGCACCGGACACCUCCAGUGACCAGACGGCAAGGUUUUUAUCCCAG	UGU	
1	AUGAUAAC GGUGUUUUUGCUGGGUUUUUCCUUGUUCGCACC GGACACCUC CAGUGAC CAGACGGCAAGGUUUUUAUCCCAG	UGU	
1	AUGAUACCUGUGUUUUUGGCUGGGUUUUUUCCUUGUACUCACCGGACACCUCCACUGCCCUCACAGGAAGGUCUUUAUCCCAG	UGUAUAUUGAAAUAACAUGCUAUA(: I
7	AAC GGUGUUUUGGCUGGGTUUUUCCUUGUUCGCACCGGACACCUCCAGUGACCAGACGGCAAGGUUUUUAUCCCAG	UGUAUAUUGGAAAAACAUGUUAUA(CUUUUGACAA
2	AUGAUAAC GGU GUUUUUG GCU GG GUUUUU CCUUGUUCG CACC GGA CACCU CCAGUGAC CAGA CG GCAAG GUUUUUAU CCCAG	UGUAUAUUGGAAAAACAUGUUAUA(CUUUUGACAA
1	GUUUUGGCUGGGUUUUUCCUUGUUCGCACCGGACACCUCCAGUGACCAGACGGCAAGGUUUUUAUCCCAG	UGUGUAUUGGAAAAACAUGUUAUA(CUUUUGACAA
4	GCUGGCUUUUUCCUUGUUCGCACCGGACACCUCCAGUGACCAGACGGCAAGCUUUUUUUCCCAG	UGUAUAUUGGAAAAACAUGUUAUA(CUUUUGACAA
з	GGACACCUC CAGUGAC CAGACGGCAAGGUUUUUUUUCCCCAG	UGUAUAUUGGAAAAACAUGUUAUA(CUUUUGACAA
2	A GUGAC CAGA CGGCAAG GUUUUUAUC CCAG	UGUAUAUUGGAAAAACAUGUUAUA(CUUUUGACAA
2	C CAGACGGCGAGGUUUUUAUCCCAG	UGUAUAUUGGAAAAACAUGUUAUA(CUUUUGACAA
1	AAGGUUAUUAUCCC	AGUGUAUACGGGAAACAUAUUAUA	CUUUUGACAA
5	AUCCCAG	UGUAUAUUGGAAAAACAUGUUAUA(CUUUUGACAA
з		UAUUGGAAAAACAUGUUAUA(CUUUUGACAA
2		AUUGGAAAAACAUGUUGUA(CUUUUGACAA
2		UAUUGGAAAAACAUGUUAUA(CUUUUGACAA
1		AUUGGAAAAACAUGUUAUA(CUUUUGACAA
1		AUUGGAAAAACAUGUUAUA(CUUUUGAC
1		GAAAAACAUGUUAUA(CUUUUGACAA

Fig. S1. Alignments of the CLIP sequences to PAN in ORF57 CLIP assays. (A) The CLIP sequence tags clustered in the 5' PAN. (B) The CLIP sequence tags clustered in an internal region of PAN. (C) The CLIP sequence tags in the 3' PAN. The 79-nt ENE (29554-29632) is highlighted in blue. Numbers on the left of (A), (B) and (C) are sequence tag frequency in ORF57 CLIP assays. The nts in red color are highly conserved nts among the identified sequence tags.